Literature DB >> 17593003

Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats.

Nami Okamura1, Maki Saito, Asami Mori, Kenji Sakamoto, Sokichi Kametaka, Tsutomu Nakahara, Kunio Ishii.   

Abstract

PURPOSE: The aim of this study was to examine the vasodilator effect of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats (SHRSPs) and in age-matched normotensive Wistar-Kyoto rats (WKYs).
METHODS: Rats (12-14 weeks-old) were anesthetized with thiobutabarbital (120 mg/kg, intraperitoneal). Fundus images were captured with a digital camera that was equipped with a special objective lens. The vasodilator responses of retinal arterioles were assessed by measuring changes in the diameters of the vessels.
RESULTS: The baseline diameter of the retinal arteriole was significantly smaller in SHRSPs than in WKYs. Fasudil (50-200 microg/kg/min, intravenous) dose-dependently increased the diameter of the retinal arteriole and decreased the systemic blood pressure in both groups. The vasodilator effect of fasudil on the retinal arteriole in SHRSPs was greater than in WKYs.
CONCLUSIONS: These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593003     DOI: 10.1089/jop.2006.128

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  9 in total

1.  Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.

Authors:  Siu-Lung Chan; Marilyn J Cipolla
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-30       Impact factor: 6.200

2.  Tanshinone II a protects against lipopolysaccharides-induced endothelial cell injury via Rho/Rho kinase pathway.

Authors:  Wei Li; Wei Sun; Chuan-hua Yang; Hong-zhen Hu; Yue-hua Jiang
Journal:  Chin J Integr Med       Date:  2014-03-04       Impact factor: 1.978

3.  The role of Rho/Rho-kinase pathway in the expression of ICAM-1 by linoleic acid in human aortic endothelial cells.

Authors:  Chang Hee Jung; Woo Je Lee; Jenie Yoonoo Hwang; So Mi Seol; Yun Mi Kim; Yoo La Lee; Ji Hyun Ahn; Joong-Yeol Park
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

4.  Combined intravitreal injection of bevacizumab and a ROCK inhibitor (fasudil) for refractory macular edema secondary to retinal vein occlusion: a pilot study.

Authors:  Sahba Fekri; Ramin Nourinia; Babak Rahimi-Ardabili; Arash Daneshtalab; Hamideh Sabbaghi; Hamid Ahmadieh; Bahareh Kheiri
Journal:  Int J Retina Vitreous       Date:  2022-06-11

5.  Next-generation sequencing analysis of gene regulation in the rat model of retinopathy of prematurity.

Authors:  Rachel M Griffith; Hu Li; Nan Zhang; Tara L Favazza; Anne B Fulton; Ronald M Hansen; James D Akula
Journal:  Doc Ophthalmol       Date:  2013-06-18       Impact factor: 2.379

6.  ROCK as a Therapeutic Target of Diabetic Retinopathy.

Authors:  Ryoichi Arita; Yasuaki Hata; Tatsuro Ishibashi
Journal:  J Ophthalmol       Date:  2010-06-21       Impact factor: 1.909

Review 7.  The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015.

Authors:  Xiaoling Chen; Kewei Wang
Journal:  Acta Pharm Sin B       Date:  2016-07-28       Impact factor: 11.413

8.  Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.

Authors:  Ryoichi Arita; Yasuaki Hata; Shintaro Nakao; Takeshi Kita; Muneki Miura; Shuhei Kawahara; Souska Zandi; Lama Almulki; Faryan Tayyari; Hiroaki Shimokawa; Ali Hafezi-Moghadam; Tatsuro Ishibashi
Journal:  Diabetes       Date:  2008-10-07       Impact factor: 9.461

9.  Calycosin-7-O-β-D-glucoside promotes oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cells.

Authors:  Yue-Hua Jiang; Wei Sun; Wei Li; Hong-Zhen Hu; Le Zhou; Hui-Hui Jiang; Jing-Xin Xu
Journal:  BMC Complement Altern Med       Date:  2015-09-07       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.